Literature DB >> 25912319

The comparative utility of fluorescence in situ hybridization and reverse transcription-polymerase chain reaction in the diagnosis of alveolar rhabdomyosarcoma.

Khin Thway1, Jayson Wang, Dorte Wren, Melissa Dainton, David Gonzalez, John Swansbury, Cyril Fisher.   

Abstract

Fluorescence in situ hybridization (FISH) for FOXO1 gene rearrangement and reverse transcription-polymerase chain reaction (PCR) for PAX3/7-FOXO1 fusion transcripts have become routine ancillary tools for the diagnosis of alveolar rhabdomyosarcomas (ARMS). Here we summarize our experience of these adjunct diagnostic modalities at a tertiary center, presenting the largest comparative series of FISH and PCR for suspected or possible ARMS to date. All suspected or possible ARMS tested by FISH or PCR for FOXO1 rearrangement or PAX3/7-FOXO1 fusion transcripts over a 7-year period were included. FISH and PCR results were correlated with clinical and histologic findings. One hundred samples from 95 patients had FISH and/or PCR performed. FISH had higher rates of technical success (96.8 %) compared with PCR (88 %). Where both tests were utilized successfully, there was high concordance rate between them (94.9 %). In 24 histologic ARMS tested for FISH or PCR, 83.3 % were translocation-positive (all for PAX3-FOXO1 by PCR) and included 3 histologic solid variants. In 76 cases where ARMS was excluded, there were 3 potential false-positive cases with FISH but none with PCR. PCR had similar sensitivity (85.7 %) and better specificity (100 %) in aiding the diagnosis of ARMS, compared with FISH (85 and 95.8 %, respectively). All solid variant ARMS harbored FOXO1 gene rearrangements and PAX3-FOXO1 ARMS were detected to the exclusion of PAX7-FOXO1. In comparative analysis, both FISH and PCR are useful in aiding the diagnosis of ARMS and excluding its sarcomatous mimics. FISH is more reliable technically but has less specificity than PCR. In cases where ARMS is in the differential diagnosis, it is optimal to perform both PCR and FISH: both have similar sensitivities for detecting ARMS, but FISH may confirm or exclude cases that are technically unsuccessful with PCR, while PCR can detect specific fusion transcripts that may be useful prognostically.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25912319     DOI: 10.1007/s00428-015-1777-9

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  39 in total

Review 1.  Pathologic classification of rhabdomyosarcomas and correlations with molecular studies.

Authors:  D M Parham
Journal:  Mod Pathol       Date:  2001-05       Impact factor: 7.842

2.  Interphase fluorescence in situ hybridization detection of t(2;13)(q35;q14) in alveolar rhabdomyosarcoma--a diagnostic tool in minimally invasive biopsies.

Authors:  A P McManus; M A O'Reilly; K P Jones; B A Gusterson; C D Mitchell; C R Pinkerton; J M Shipley
Journal:  J Pathol       Date:  1996-04       Impact factor: 7.996

3.  Utility of sarcoma-specific fusion gene analysis in paraffin-embedded material for routine diagnosis at a specialist centre.

Authors:  Khin Thway; Sasha Rockcliffe; David Gonzalez; John Swansbury; Toon Min; Lisa Thompson; Cyril Fisher
Journal:  J Clin Pathol       Date:  2010-05-03       Impact factor: 3.411

4.  Consistent chromosomal translocation in alveolar rhabdomyosarcoma.

Authors:  C Turc-Carel; S Lizard-Nacol; E Justrabo; M Favrot; T Philip; E Tabone
Journal:  Cancer Genet Cytogenet       Date:  1986-01-15

5.  Common and variant gene fusions predict distinct clinical phenotypes in rhabdomyosarcoma.

Authors:  K M Kelly; R B Womer; P H Sorensen; Q B Xiong; F G Barr
Journal:  J Clin Oncol       Date:  1997-05       Impact factor: 44.544

6.  PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification.

Authors:  Edoardo Missiaglia; Dan Williamson; Julia Chisholm; Pratyaksha Wirapati; Gaëlle Pierron; Fabien Petel; Jean-Paul Concordet; Khin Thway; Odile Oberlin; Kathy Pritchard-Jones; Olivier Delattre; Mauro Delorenzi; Janet Shipley
Journal:  J Clin Oncol       Date:  2012-03-26       Impact factor: 44.544

7.  Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas.

Authors:  Elai Davicioni; Friedrich Graf Finckenstein; Violette Shahbazian; Jonathan D Buckley; Timothy J Triche; Michael J Anderson
Journal:  Cancer Res       Date:  2006-07-15       Impact factor: 12.701

8.  JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells.

Authors:  Z S Walters; B Villarejo-Balcells; D Olmos; T W S Buist; E Missiaglia; R Allen; B Al-Lazikani; M D Garrett; J Blagg; J Shipley
Journal:  Oncogene       Date:  2013-02-25       Impact factor: 9.867

9.  Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma.

Authors:  N Galili; R J Davis; W J Fredericks; S Mukhopadhyay; F J Rauscher; B S Emanuel; G Rovera; F G Barr
Journal:  Nat Genet       Date:  1993-11       Impact factor: 38.330

10.  Molecular assays for chromosomal translocations in the diagnosis of pediatric soft tissue sarcomas.

Authors:  F G Barr; J Chatten; C M D'Cruz; A E Wilson; L E Nauta; L M Nycum; J A Biegel; R B Womer
Journal:  JAMA       Date:  1995-02-15       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.